Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

Ye Yao; Xiaoya Xu; Lifeng Yang; Ji Zhu; Juefeng Wan; Lijun Shen; Fan Xia; Guoxiang Fu; Yun Deng; Mengxue Pan; Qiang Guo; Xiaoxue Gao; Yuanchuang Li; Xinxin Rao; Yi Zhou; Liping Liang; Yaqi Wang; Jing Zhang; Hui Zhang; Guichao Li; Lixing Zhang; Junjie Peng; Sanjun Cai; Chen Hu; Jianjun Gao; Hans Clevers; Zhen Zhang; Guoqiang Hua

doi:10.1016/j.stem.2019.10.010

Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

Ye Yao, Xiaoya Xu, Lifeng Yang, Ji Zhu, Juefeng Wan, Lijun Shen, Fan Xia, Guoxiang Fu, Yun Deng, Mengxue Pan, Qiang Guo, Xiaoxue Gao, Yuanchuang Li, Xinxin Rao, Yi Zhou, Liping Liang, Yaqi Wang, Jing Zhang, Hui Zhang, Guichao LiLixing Zhang, Junjie Peng, Sanjun Cai, Chen Hu, Jianjun Gao, Hans Clevers, Zhen Zhang, Guoqiang Hua

Hubrecht Institute

Research output: Contribution to journal/periodical › Article › Scientific › peer-review

425 Citations (Scopus)

Abstract

Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in cancer patients remains an open question. Here we generate a living organoid biobank from patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled in a phase III clinical trial. Our co-clinical trial data confirm that rectal cancer organoids (RCOs) closely recapitulate the pathophysiology and genetic changes of corresponding tumors. Chemoradiation responses in patients are highly matched to RCO responses, with 84.43% accuracy, 78.01% sensitivity, and 91.97% specificity. These data imply that PDOs predict LARC patient responses in the clinic and may represent a companion diagnostic tool in rectal cancer treatment.

Original language	English
Pages (from-to)	17-26.e6
Journal	Cell Stem Cell
Volume	26
Issue number	1
DOIs	https://doi.org/10.1016/j.stem.2019.10.010
Publication status	Published - 02 Jan 2020

Access to Document

10.1016/j.stem.2019.10.010

Cite this

@article{9d1c7fca78b44dd98dda75da983c62ec,

title = "Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer",

abstract = "Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in cancer patients remains an open question. Here we generate a living organoid biobank from patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled in a phase III clinical trial. Our co-clinical trial data confirm that rectal cancer organoids (RCOs) closely recapitulate the pathophysiology and genetic changes of corresponding tumors. Chemoradiation responses in patients are highly matched to RCO responses, with 84.43% accuracy, 78.01% sensitivity, and 91.97% specificity. These data imply that PDOs predict LARC patient responses in the clinic and may represent a companion diagnostic tool in rectal cancer treatment.",

author = "Ye Yao and Xiaoya Xu and Lifeng Yang and Ji Zhu and Juefeng Wan and Lijun Shen and Fan Xia and Guoxiang Fu and Yun Deng and Mengxue Pan and Qiang Guo and Xiaoxue Gao and Yuanchuang Li and Xinxin Rao and Yi Zhou and Liping Liang and Yaqi Wang and Jing Zhang and Hui Zhang and Guichao Li and Lixing Zhang and Junjie Peng and Sanjun Cai and Chen Hu and Jianjun Gao and Hans Clevers and Zhen Zhang and Guoqiang Hua",

year = "2020",

month = jan,

day = "2",

doi = "10.1016/j.stem.2019.10.010",

language = "English",

volume = "26",

pages = "17--26.e6",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "1",

}

Yao, Y, Xu, X, Yang, L, Zhu, J, Wan, J, Shen, L, Xia, F, Fu, G, Deng, Y, Pan, M, Guo, Q, Gao, X, Li, Y, Rao, X, Zhou, Y, Liang, L, Wang, Y, Zhang, J, Zhang, H, Li, G, Zhang, L, Peng, J, Cai, S, Hu, C, Gao, J, Clevers, H, Zhang, Z & Hua, G 2020, 'Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer', Cell Stem Cell, vol. 26, no. 1, pp. 17-26.e6. https://doi.org/10.1016/j.stem.2019.10.010

TY - JOUR

T1 - Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

AU - Yao, Ye

AU - Xu, Xiaoya

AU - Yang, Lifeng

AU - Zhu, Ji

AU - Wan, Juefeng

AU - Shen, Lijun

AU - Xia, Fan

AU - Fu, Guoxiang

AU - Deng, Yun

AU - Pan, Mengxue

AU - Guo, Qiang

AU - Gao, Xiaoxue

AU - Li, Yuanchuang

AU - Rao, Xinxin

AU - Zhou, Yi

AU - Liang, Liping

AU - Wang, Yaqi

AU - Zhang, Jing

AU - Zhang, Hui

AU - Li, Guichao

AU - Zhang, Lixing

AU - Peng, Junjie

AU - Cai, Sanjun

AU - Hu, Chen

AU - Gao, Jianjun

AU - Clevers, Hans

AU - Zhang, Zhen

AU - Hua, Guoqiang

PY - 2020/1/2

Y1 - 2020/1/2

N2 - Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in cancer patients remains an open question. Here we generate a living organoid biobank from patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled in a phase III clinical trial. Our co-clinical trial data confirm that rectal cancer organoids (RCOs) closely recapitulate the pathophysiology and genetic changes of corresponding tumors. Chemoradiation responses in patients are highly matched to RCO responses, with 84.43% accuracy, 78.01% sensitivity, and 91.97% specificity. These data imply that PDOs predict LARC patient responses in the clinic and may represent a companion diagnostic tool in rectal cancer treatment.

AB - Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in cancer patients remains an open question. Here we generate a living organoid biobank from patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled in a phase III clinical trial. Our co-clinical trial data confirm that rectal cancer organoids (RCOs) closely recapitulate the pathophysiology and genetic changes of corresponding tumors. Chemoradiation responses in patients are highly matched to RCO responses, with 84.43% accuracy, 78.01% sensitivity, and 91.97% specificity. These data imply that PDOs predict LARC patient responses in the clinic and may represent a companion diagnostic tool in rectal cancer treatment.

U2 - 10.1016/j.stem.2019.10.010

DO - 10.1016/j.stem.2019.10.010

M3 - Article

C2 - 31761724

SN - 1934-5909

VL - 26

SP - 17-26.e6

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 1

ER -

Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

Abstract

Access to Document

Fingerprint

Cite this